Once-daily, extended-release gemfibrozil in patients with dyslipidemia

Antonio M. Gotto, William J. Breen, Clinton N. Corder, J. Kay Dunn, Anne Goldberg, Robert H. Knopp, Helmut Schrott, Dennis Sprecher

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

This randomized, parallel-group, multicenter clinical trial compared a newly developed, once-daily, extended-release formulation of gemfibrozil (Lopid SR®) and gemfibrozil twice daily (Lopid®) in terms of lipid-regulating effects and toxicity. Patients were men and women with elevations of low-density lipoprotein cholesterol and low levels of high-density lipoprotein cholesterol. The trial consisted of a 1-week screening period, an 8-week diet baseline period (Step One Diet), and a 24-week double-blind treatment period (extended-release gemfibrozil 1,200 mg once daily vs gemfibrozil 600 mg twice daily). At the end of the trial, the 2 treatment groups showed comparable improvements in all primary lipid factors: mean percent changes in triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were -32, +10 and -10% for extended release (n = 325) and -36, +11 and -10% for twice daily (n = 330). The 90% confidence interval for the relative difference between the treatment means fell within the equivalence bounds of ±35% for all 3 factors, demonstrating equivalence of efficacy. Adverse events were reported at low rates and were similarly distributed in frequency and intensity between treatment groups; they were preponderantly mild or moderate, and gastrointestinal effects were the most frequent. The once-daily formulation of gemfibrozil may afford better control of dyslipidemia through improved compliance by patients who have this asymptomatic disease.

Original languageEnglish (US)
Pages (from-to)1057-1063
Number of pages7
JournalThe American Journal of Cardiology
Volume71
Issue number12
DOIs
StatePublished - May 1 1993

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Once-daily, extended-release gemfibrozil in patients with dyslipidemia'. Together they form a unique fingerprint.

Cite this